AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05807412
Drug: PrabotulinumtoxinA-Xvfs
RxNorm normalized name: prabotulinumtoxinA-xvfs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will receive one injection of 4 units or 0.1 cc of prabotulinumtoxin A into the frontalis at a single point 2.5 cm above the orbital rim at the mid-pupillary line.~The preparation of the 100-unit vial of prabotulinumtoxinA will be reconstituted gently and without shaking with 2.5 cc of 0.9% preserved normal saline solution. The investigator performing the injections will reconstitute study vials.~Subjects will be injected intramuscularly using a hubless tuberculin syringe. Injections will be done at a 90-degree angle or perpendicular to the skin surface. The target sites will be the mid-line of the pupil and 2.5 cm above the orbital rim.
Trial: NCT06123715
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Patients in the placebo group will receive identical placebo capsules taken orally within 4 hours of the start of the surgery followed by placebo capsules taken orally twice a day from post-op day 1 to day 56.
Trial: NCT06543459
Drug: MY008211A tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects of Group A receive MY008211A tablets on Day 1 of both Sequence, wash-out period is 6 Days at least.
Trial: NCT06543459
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects of Group A receive placebo tablets on Day 1 of both Sequence, wash-out period is 6 Days at least.
Trial: NCT05985655
Drug: GTAEXS617
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GTAEXS617 tablets daily
Trial: NCT02497222
Drug: RNS60
RxNorm normalized name: Ronasin 60
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02497222
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03481842
Drug: BIBW2992
FDA approved: no
EMA approved: no
PMDA approved: no
Description: in a minimally sufficient therapeutic dose
Trial: NCT05103215
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of 1.5 mg/kg normal saline at induction of anesthesia and continuous infusion of 1.5 mg/kg/h (ideal body weight) through the maintenance period to one hour after operation.
Trial: NCT03068247
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 week treatment
Trial: NCT05337592
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04325958
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750mg cigarette of plant material
Trial: NCT04777006
Drug: Antidepressant Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine, a serotonin selective reuptake inhibitor (SSRI), and amitriptyline, a tricyclic antidepressant (TCA), are part of Malawi's national formulary. Neno District supply chain is supported by PIH, which reduces stock-outs relative to those observed in other Malawian settings. Fluoxetine is typically the first drug of choice because it is safer and better tolerated.~Daily dose will commence at 20 mg of fluoxetine, or 25 mg of amitriptyline. At monthly follow-up visits, a dose increment or medication change may be considered based on measures of treatment response and side effects, using an Antidepressant Side Effect Checklist. This algorithm-based process will be repeated every other week until the patient is fully responding to treatment (PHQ-9 \< 5) for a period of three months. Dose escalations of more than one increment and medication changes will be reviewed with the doctor-in-charge. If on ADT at end of study, it will be sustained as part of usual care.
Trial: NCT05850819
Drug: Sterile gauze pack
RxNorm normalized name: GAUZE,STERILE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extraction socket allowed to heal without augmentation with any material
Trial: NCT05487742
Drug: placebo salin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: salin infused as aplacebo for 72 hours
Trial: NCT05305872
Drug: Gandouling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The experimental group was given gandouling tablet + zinc gluconate simulant; The course of treatment was 24 weeks.
Trial: NCT05135039
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 100mg/day/patient
Trial: NCT05708573
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In Treatment Period 1, participants will receive a single oral tablet of rosuvastatin in the morning of Day 1. In treatment period 2, on the morning of Day 4, participants will receive a single 20 mg dose of rosuvastatin (co-administered with the morning dose of ALXN2040).
Trial: NCT05708573
Drug: ALXN2040
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Treatment Period 2, participants will receive oral tablets of ALXN2040 three times daily on Days 1 through 7.
Trial: NCT01882712
Drug: CD07805/47 Gel 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01882712
Drug: CD07805/47 Gel Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05046873
Drug: NNC0480-0389 A 10 mg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants will be receive a subcutaneus (s.c) injection of 0.5 mg semaglutide and 5 mg NNC0480 0389 on two separate doing visits separated by at least 8 weeks.
Trial: NCT05792163
Drug: SNP318 (A)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule for oral administration
Trial: NCT05792163
Drug: Placebo (B)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules matching the SNP318 capsules
Trial: NCT04855240
Drug: ACP-044 Dose A
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dose of ACP-044 Dose A
Trial: NCT04855240
Drug: ACP-044 Dose B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose of ACP-044 Dose B
Trial: NCT04855240
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose of placebo
Trial: NCT05348681
Drug: RIST4721
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIST4721 tablets, 100 mg are blue, oval, biconvex film-coated tablets
Trial: NCT05348681
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT04901663
Drug: Omeprazole 20 MG Capsule; Amoxicillin 1000 MG; Clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally twice daily for 2 weeks
Trial: NCT06632613
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules will be orally administered once a day for 5 consecutive days based on the standard treatment after cardiac surgery. If the subject is unable to swallow the investigational product autonomously, the capsules will be administrated through a nasogastric tube/oral gastric tube.
Trial: NCT04767061
Drug: Beta blockers
RxNorm normalized name: BETA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention is a two-arm crossover withdrawal/ reversal design (On \[A\] vs Off \[B\]) with up to 4 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta blocker. During the Off period (B), their beta blockers will be down titrated and subsequently discontinued.~Subjects will be randomized into either ABAB or BABA sequences.
Trial: NCT06036576
Drug: Levothyroxine Pill
RxNorm normalized name: levothyroxine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: all participants will receive levothyroxine treatment of 1.6 micrograms per kg per day early in the morning on empty stomach.
Trial: NCT06523504
Drug: The 0.02% ATP Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: wear SP, and use 0.02%ATP eye drops, once nightly, both eye
Trial: NCT06523504
Drug: The 0.04% ATP Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: wear SP, and use 0.04%ATP eye drops, once nightly, both eye
Trial: NCT05860907
Drug: Huaier Granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10g each time, three times a day
Trial: NCT04790006
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT04877379
Drug: VNRX-7145
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-lactamase inhibitor
Trial: NCT04877379
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05623267
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of Sugemalimab
Trial: NCT04915755
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered
Trial: NCT00000954
Drug: Doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06293885
Drug: Dextrose 50
RxNorm normalized name: DEXTROSE 50% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a solution of 50% glucose (D50) will be injected into your pleural space
Trial: NCT04727229
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of Normal Saline near the stellate ganglion
Trial: NCT05055609
Drug: TRE-515
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRE-515 will be administered orally once daily at least 1 hour prior or 2 hours after eating at approximately the same time each day. Dosing will be continuous with no breaks between cycles. Subjects will continue to receive successive cycles of TRE-515 treatment as long as they do not demonstrate progressive disease, experience an unacceptable toxicity, and both the Sponsor and PI consider additional treatment with TRE-515 to be within the best interest of the subject.
Trial: NCT04778189
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: while patients in group( NS ) will receive 500-mL normal saline IV in 5-10 minutes, after spinal anesthesia
Trial: NCT04778189
Drug: i.v dexmethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients in group( SD )will receive 8-mg dexamethasone IV in 500-mL normal saline after spinal anesthesia
Trial: NCT04723940
Drug: Doxycycline Hcl
RxNorm normalized name: doxycycline HCl
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline HCl will given for 6 weeks to treat joint infection
Trial: NCT04723940
Drug: Clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin will given for 6 weeks to treat joint infection
Trial: NCT06181838
Drug: Tretinoin
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tretinoin and benzoil peroxide used concurent in both groups as standard therapy
Trial: NCT04540289
Drug: Optimal Medical Therapy (OMT)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated according to Optimal Medical Therapy defined by the following guidelines:~1. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes~2. 2016 ESC guidelines for the management of acute and chronic heart failure
Trial: NCT05133518
Drug: MELT-300
RxNorm normalized name: Feldene Melt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual tablet
Trial: NCT05133518
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual tablet
Trial: NCT05079802
Drug: Double antibiotic paste mixed with propylene glycol
RxNorm normalized name: Propylene Glycol
DrugBank: Propylene glycol (DB01839)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lesion sterilization and tissue repair in non-vital primary molars with double antibiotic paste mixed with propylene glycol
Trial: NCT06039423
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: conventional general anaesthesia receiving multimodal analgesia
Trial: NCT05070312
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00000751
Drug: Anti-HIV Immune Serum Globulin (Human)
RxNorm normalized name: immune globulin subcutaneous (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00000751
Drug: Globulin, Immune
RxNorm normalized name: globulin, immune
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04821206
Drug: DMARDs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New Initiation of a DMARDs
Trial: NCT04821206
Drug: JAK Inhibitor
RxNorm normalized name: Janus-associated kinase (JAK) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New Initiation of a JAK Inhibitor
Trial: NCT05597540
Drug: Usual antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 day-duration antibiotic treatment. The choice of antibiotic treatment is left to the medical team in charge of the patient.
Trial: NCT05980065
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneously administrate placebo at 0 Day 1, Day 8, Day 15
Trial: NCT06112028
Drug: Tongxinluo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On the basis of conventional treatment, the study participants in the experimental group were given Tongxinluo capsule for 12 months.
Trial: NCT04707261
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo 10 mg once daily
Trial: NCT05263570
Drug: Standard Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Therapy, including TCbHP, THP, EC-THP, AC-THP
Trial: NCT05275647
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LESW treatment with 3000 shocks, frequency of 3 pulses per second, and maximum total energy flow density 0.25 mJ/mm2 , and followed by intravesical instillation of 30ml normal saline retained in the bladder for 2 hours after LESW application, every one week for 4 times.
Trial: NCT05125328
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First start with remifentanil 6.0 ng/ml, and use the up and down method as adjust 0.5 ng/ml of concentration of remifentanil each time. An ANI lower than 30 and hyperdynamics (the increased heart rate and mean blood pressure up 20% of baseline or heart rate\>100bpm and arterial blood pressure\>180/100mmHg) indicates insufficient analgesia, therefore increase it by 0.5 ng/ml; an ANI higher than 30 and stable hemodynamics (the changes of HR and MBP within 20% of baseline or HR\<50bpm and ABP\<90/50mmHg) indicates that analgesia is acceptable, and the next patient will decrease it by 0.5 ng/ml during skull pin fixation.
Trial: NCT04891900
Drug: TQB2450/Anlotinib hydrochloride/Oxaliplatin/Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial treatment (6 cycles)：~1. TQB2450：1200 mg , Day 1 ivgtt ,once every 3 weeks~2. Anlotinib: 10 mg/day orally ，from days 1 to 14 in a 21-day cycle~3. Oxaliplatin: 130 mg / m2, Day 1 ivgtt ,once every 3 weeks~4. Capecitabine: 1000 mg / m2, orally, twice a day (once in the morning and once in the evening), from days 1 to 14 in a 21-day cycle Maintenance treatment：~1）TQB2450: 1200 mg , Day 1 ivgtt , once every 3 weeks 2）Anlotinib: 10 mg/day orally , from days 1 to 14 in a 21-day cycle
Trial: NCT05270954
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: a 0.9% NaCl intramuscular injection solution (0.5 ml)
Trial: NCT04713826
Drug: BAY2586116
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 µg, nasal spray administration.
Trial: NCT04713826
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching BAY2586116, nasal spray administration.
Trial: NCT06328153
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants in the drug group will receive celecoxib (capsule) 200mg every day continuously for 2 weeks.
Trial: NCT05767632
Drug: Vesicare (Solifenacin Succinate 5 mg) & Betmiga (Mirabegron 50 mg) (Reference first dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet Vesicare contains Solifenacine succinate 5 mg \& 1 tablet Betmiga contains Mirabegron 50 mg orally administrated followed by 240 ml of water
Trial: NCT05767632
Drug: Vesicare (Solifenacin Succinate 5 mg) & Betmiga (Mirabegron 50 mg) (Reference second dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet Vesicare contains Solifenacine succinate 5 mg \& 1 tablet Betmiga contains Mirabegron 50 mg orally administrated followed by 240 ml of water
Trial: NCT04147065
Drug: Duration of eradication regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 day eradication regimen
Trial: NCT04611763
Drug: Flurbiprofen axetil preoperatively
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: give Flurbiprofen axetil 15 min before surgery
Trial: NCT04611763
Drug: Flurbiprofen axetil postoperatively
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: give Flurbiprofen axetil at the end of surgery
Trial: NCT04779255
Drug: Procedure (Tumesent anesthesia)
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Photodynamic therapy of vertex with a solution of 180 ml of tumescent anesthesia diffused over 1 hour in three different sub-deceasing points.
Trial: NCT05608044
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regorafenib or trifluridine and tipiracil.
Trial: NCT04822818
Drug: SOC
RxNorm normalized name: Isocet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will receive the best of standard of care including corticosteroids, anticoagulant, antibiotics and tociluzimab
Trial: NCT06353152
Drug: Claudin18.2-Targeted Chimeric Antigen Receptor T Cell Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single-/multiple-dose infusion
Trial: NCT04719481
Drug: Pravastatin Sodium 80 MG
RxNorm normalized name: pravastatin sodium 80 MG
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: daily oral administration of 80mg
Trial: NCT04719481
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily oral administration
Trial: NCT05889793
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant takes a placebo for 10 consecutive days.
Trial: NCT04976790
Drug: Flurbiprofen Cataplasms group (FCG).
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One Flurbiprofen Cataplasm was applied to the left and right sides of the waist, twice daily, for 14 days
Trial: NCT05274516
Drug: HRS-2261 tablet、placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS-2261 oral tablet, oral, single dose. Matching placebo to HRS-2261, oral, single dose.
Trial: NCT05274516
Drug: HRS-2261 tablet、placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS-2261 oral tablet, oral, BID. Matching placebo to HRS-2261, oral, BID.
Trial: NCT06400589
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same composition as tanfanercept but without the active ingredient
Trial: NCT05034042
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT05478512
Drug: VenObi+Ven or VenObi+VenZan
RxNorm normalized name: Apis mellifera ven protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive obinutuzumab 1000mg IV (cycle 1: day 1,8,15; Cycle2-6: day1) + venetoclax 400mg/d (preceded by a ramp-up phase) until cycle 9, day 28.~At cycle9:~* if uMRD = Venetoclax 400 mg/d orally until cycle 13.~* if residual disease in the BM or PB = Venetoclax 400 mg/d + Zanubrutinib 160 mg orally twice daily until cycle 21.~then, at cycle 21:~* if uMRD = stop treatment~* if residual disease in the BM or PB = zanubrutinib 160 mg orally twice daily until disease progression
Trial: NCT05294484
Drug: Indapamide 1.5 MG SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the effect of genetic variation of UGT2B7 on human response to treatment with indapamide and its correlation with pharmacokinetic parameters in Egyptian subjects
Trial: NCT06182098
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5mg/kg, with a maximum of 30mg
Trial: NCT05653401
Drug: Magnesium sulfate and diclofenac
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intramuscular injection of 75 mg/ 3 ml of Diclofenac solution Intravenous injection of 1 g of Magnesium Sulfate solution diluted in 10 ml of saline solution administered over 2 to 4 minutes
Trial: NCT05653401
Drug: Lidocain and diclofenac
RxNorm normalized name: diclofenac / lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of 75 mg/ 3 ml of Diclofenac solution Intravenous injection of 10 ml of Lidocaine 1% solution administered over 2 to 4 minutes.
Trial: NCT05653401
Drug: Placebo and diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of 75 mg of Diclofenac solution and 10 ml Intravenous injection of serum saline ( as a Placebo Comparator ) administered over 2 to 4 minutes.
Trial: NCT05034809
Drug: Melatonin 20 MG
RxNorm normalized name: melatonin 20 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin, also known as N-acetyl-5-methoxytryptamine will be the main intervention given to participating patients of this study. This study will use a dose of 20mg/day using the commercially available 5mg/tablet20-21. If a patient cannot be tolerate swallowing the whole tablet, it will be crushed and mixed with milk. According to the study done by Shah et al. there was no degradation in the active component of melatonin when mixed with milk or food as a medium for drug delivery.